CLINICAL TRIALS PROFILE FOR SPECTINOMYCIN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for SPECTINOMYCIN HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02099240 ↗ | Patients Response to Early Switch To Oral:Osteomyelitis Study | Terminated | James Graham Brown Cancer Center | Early Phase 1 | 2014-03-06 | Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective. |
| NCT02099240 ↗ | Patients Response to Early Switch To Oral:Osteomyelitis Study | Terminated | University of Louisville | Early Phase 1 | 2014-03-06 | Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective. |
| NCT02099240 ↗ | Patients Response to Early Switch To Oral:Osteomyelitis Study | Terminated | Julio Ramirez | Early Phase 1 | 2014-03-06 | Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective. |
| NCT05327972 ↗ | DEgenerative ROtator Cuff Disease and Botulinum TOXin: a Randomized Trial | Not yet recruiting | Merz Pharmaceuticals GmbH | Phase 2 | 2022-06-01 | The aim of the study is to assess the effectiveness of botulinum toxin in persistent shoulder pain due to degenerative rotator cuff disease. |
| NCT05327972 ↗ | DEgenerative ROtator Cuff Disease and Botulinum TOXin: a Randomized Trial | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | Phase 2 | 2022-06-01 | The aim of the study is to assess the effectiveness of botulinum toxin in persistent shoulder pain due to degenerative rotator cuff disease. |
| NCT05340439 ↗ | INcobotulinumtoxina in ChIldren Upper and Lower Limb sPasticITy (INCIPIT) | Not yet recruiting | Universita di Verona | Phase 2 | 2022-06-01 | Prospective, open-label, non-randomized, single-arm, dose titration, phase II study. The study will consist of three injection cycles. In each, an injection visit is followed by an observation period of 12 to 20 weeks. During cycle 1, a total body dose of 16U/kg (maximum 400U) of IncobotulinumtoxinA will be injected into the spastic muscles of the affected limbs. During cycle 2, a total body dose of 19U/kg (maximum 475U) of IncobotulinumtoxinA will be injected into the spastic muscles of the affected limbs. If a dose of 19U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 1 (16U/Kg; maximum 400U) may be administered in the cycle 2. During cycle 3, a total body dose of 22U/kg (maximum 550U) of IncobotulinumtoxinA will be injected into the spastic muscles of the affected limbs. If a dose of 22U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 2 (19U/Kg; maximum 475U) may be administered in the cycle 3. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SPECTINOMYCIN HYDROCHLORIDE
Condition Name
Clinical Trial Locations for SPECTINOMYCIN HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for SPECTINOMYCIN HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for SPECTINOMYCIN HYDROCHLORIDE
Sponsor Name
